Persistent anxiolytic affects after chronic administration of the CRF 1 receptor antagonist R121919 in rats

David A. Gutman, Michael J. Owens, K. V. Thrivikraman, Charles Nemeroff

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Corticotropin-releasing factor (CRF) functions as one of the major mediators of the mammalian stress response and appears to play a key role in the pathophysiology of mood and anxiety disorders. Small molecule CRF 1 receptor antagonists may represent a novel form of pharmacotherapy for these disorders. The therapeutic success of CRF 1 receptor antagonists will depend, in part, upon whether tolerance develops to the actions of these compounds and whether appropriate patterns of HPA axis function is maintained. This study evaluated the effects of long term (∼4 week) treatment with the CRF 1 receptor antagonist R121919, on CRF receptor function, HPA axis activity, behavioral measures, adrenal gland size, and body weight gain. Animals treated with 20 mg/kg/day of R121919 spent significantly more time in the open field in a defensive withdrawal test (138 ± 36 s for R121919 vs 52 ± 12 s for vehicle, p = 0.01). No significant effect of chronic CRF 1 receptor blockade on basal ACTH or corticosterone concentrations were detected, nor were significant changes detected in an elevated plus maze test. Both vehicle- and R121919- treated rats showed increases in AUC and peak ACTH and corticosterone concentrations following air puff startle stress, without any overall group differences, although a clear but non-significant attenuation in HPA axis response was observable in R121919 treated animals. Chronic CRF 1 receptor blockade increased CRF peptide mRNA expression in the PVN and decreased CRF peptide mRNA expression in the central nucleus of the amygdala. Overall our results suggest that anxiolytic effects of chronic CRF 1 receptor antagonism persist following chronic administration without significant attenuation of the HPA axis's ability to mount a stress response. This article is part of a Special Issue entitled 'Trends in Neuropharmacology: In Memory of Erminio Costa'.

Original languageEnglish
Pages (from-to)1135-1141
Number of pages7
JournalNeuropharmacology
Volume60
Issue number7-8
DOIs
StatePublished - Jun 1 2011

Fingerprint

R 121919
Anti-Anxiety Agents
Corticotropin-Releasing Hormone
Corticosterone
Adrenocorticotropic Hormone
Neuropharmacology
Corticotropin-Releasing Hormone Receptors
Messenger RNA
Peptides
Adrenal Glands
Anxiety Disorders
Mood Disorders
Weight Gain
Area Under Curve
CRF receptor type 1
Air
Body Weight
Drug Therapy

Keywords

  • Animal models
  • CRF
  • CRF antagonist
  • CRH
  • NBI-30775
  • R121919

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Persistent anxiolytic affects after chronic administration of the CRF 1 receptor antagonist R121919 in rats. / Gutman, David A.; Owens, Michael J.; Thrivikraman, K. V.; Nemeroff, Charles.

In: Neuropharmacology, Vol. 60, No. 7-8, 01.06.2011, p. 1135-1141.

Research output: Contribution to journalArticle

Gutman, David A. ; Owens, Michael J. ; Thrivikraman, K. V. ; Nemeroff, Charles. / Persistent anxiolytic affects after chronic administration of the CRF 1 receptor antagonist R121919 in rats. In: Neuropharmacology. 2011 ; Vol. 60, No. 7-8. pp. 1135-1141.
@article{763be713eae94fe7a7c142a952591b64,
title = "Persistent anxiolytic affects after chronic administration of the CRF 1 receptor antagonist R121919 in rats",
abstract = "Corticotropin-releasing factor (CRF) functions as one of the major mediators of the mammalian stress response and appears to play a key role in the pathophysiology of mood and anxiety disorders. Small molecule CRF 1 receptor antagonists may represent a novel form of pharmacotherapy for these disorders. The therapeutic success of CRF 1 receptor antagonists will depend, in part, upon whether tolerance develops to the actions of these compounds and whether appropriate patterns of HPA axis function is maintained. This study evaluated the effects of long term (∼4 week) treatment with the CRF 1 receptor antagonist R121919, on CRF receptor function, HPA axis activity, behavioral measures, adrenal gland size, and body weight gain. Animals treated with 20 mg/kg/day of R121919 spent significantly more time in the open field in a defensive withdrawal test (138 ± 36 s for R121919 vs 52 ± 12 s for vehicle, p = 0.01). No significant effect of chronic CRF 1 receptor blockade on basal ACTH or corticosterone concentrations were detected, nor were significant changes detected in an elevated plus maze test. Both vehicle- and R121919- treated rats showed increases in AUC and peak ACTH and corticosterone concentrations following air puff startle stress, without any overall group differences, although a clear but non-significant attenuation in HPA axis response was observable in R121919 treated animals. Chronic CRF 1 receptor blockade increased CRF peptide mRNA expression in the PVN and decreased CRF peptide mRNA expression in the central nucleus of the amygdala. Overall our results suggest that anxiolytic effects of chronic CRF 1 receptor antagonism persist following chronic administration without significant attenuation of the HPA axis's ability to mount a stress response. This article is part of a Special Issue entitled 'Trends in Neuropharmacology: In Memory of Erminio Costa'.",
keywords = "Animal models, CRF, CRF antagonist, CRH, NBI-30775, R121919",
author = "Gutman, {David A.} and Owens, {Michael J.} and Thrivikraman, {K. V.} and Charles Nemeroff",
year = "2011",
month = "6",
day = "1",
doi = "10.1016/j.neuropharm.2010.10.004",
language = "English",
volume = "60",
pages = "1135--1141",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Elsevier Limited",
number = "7-8",

}

TY - JOUR

T1 - Persistent anxiolytic affects after chronic administration of the CRF 1 receptor antagonist R121919 in rats

AU - Gutman, David A.

AU - Owens, Michael J.

AU - Thrivikraman, K. V.

AU - Nemeroff, Charles

PY - 2011/6/1

Y1 - 2011/6/1

N2 - Corticotropin-releasing factor (CRF) functions as one of the major mediators of the mammalian stress response and appears to play a key role in the pathophysiology of mood and anxiety disorders. Small molecule CRF 1 receptor antagonists may represent a novel form of pharmacotherapy for these disorders. The therapeutic success of CRF 1 receptor antagonists will depend, in part, upon whether tolerance develops to the actions of these compounds and whether appropriate patterns of HPA axis function is maintained. This study evaluated the effects of long term (∼4 week) treatment with the CRF 1 receptor antagonist R121919, on CRF receptor function, HPA axis activity, behavioral measures, adrenal gland size, and body weight gain. Animals treated with 20 mg/kg/day of R121919 spent significantly more time in the open field in a defensive withdrawal test (138 ± 36 s for R121919 vs 52 ± 12 s for vehicle, p = 0.01). No significant effect of chronic CRF 1 receptor blockade on basal ACTH or corticosterone concentrations were detected, nor were significant changes detected in an elevated plus maze test. Both vehicle- and R121919- treated rats showed increases in AUC and peak ACTH and corticosterone concentrations following air puff startle stress, without any overall group differences, although a clear but non-significant attenuation in HPA axis response was observable in R121919 treated animals. Chronic CRF 1 receptor blockade increased CRF peptide mRNA expression in the PVN and decreased CRF peptide mRNA expression in the central nucleus of the amygdala. Overall our results suggest that anxiolytic effects of chronic CRF 1 receptor antagonism persist following chronic administration without significant attenuation of the HPA axis's ability to mount a stress response. This article is part of a Special Issue entitled 'Trends in Neuropharmacology: In Memory of Erminio Costa'.

AB - Corticotropin-releasing factor (CRF) functions as one of the major mediators of the mammalian stress response and appears to play a key role in the pathophysiology of mood and anxiety disorders. Small molecule CRF 1 receptor antagonists may represent a novel form of pharmacotherapy for these disorders. The therapeutic success of CRF 1 receptor antagonists will depend, in part, upon whether tolerance develops to the actions of these compounds and whether appropriate patterns of HPA axis function is maintained. This study evaluated the effects of long term (∼4 week) treatment with the CRF 1 receptor antagonist R121919, on CRF receptor function, HPA axis activity, behavioral measures, adrenal gland size, and body weight gain. Animals treated with 20 mg/kg/day of R121919 spent significantly more time in the open field in a defensive withdrawal test (138 ± 36 s for R121919 vs 52 ± 12 s for vehicle, p = 0.01). No significant effect of chronic CRF 1 receptor blockade on basal ACTH or corticosterone concentrations were detected, nor were significant changes detected in an elevated plus maze test. Both vehicle- and R121919- treated rats showed increases in AUC and peak ACTH and corticosterone concentrations following air puff startle stress, without any overall group differences, although a clear but non-significant attenuation in HPA axis response was observable in R121919 treated animals. Chronic CRF 1 receptor blockade increased CRF peptide mRNA expression in the PVN and decreased CRF peptide mRNA expression in the central nucleus of the amygdala. Overall our results suggest that anxiolytic effects of chronic CRF 1 receptor antagonism persist following chronic administration without significant attenuation of the HPA axis's ability to mount a stress response. This article is part of a Special Issue entitled 'Trends in Neuropharmacology: In Memory of Erminio Costa'.

KW - Animal models

KW - CRF

KW - CRF antagonist

KW - CRH

KW - NBI-30775

KW - R121919

UR - http://www.scopus.com/inward/record.url?scp=79954607391&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954607391&partnerID=8YFLogxK

U2 - 10.1016/j.neuropharm.2010.10.004

DO - 10.1016/j.neuropharm.2010.10.004

M3 - Article

C2 - 20951149

AN - SCOPUS:79954607391

VL - 60

SP - 1135

EP - 1141

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

IS - 7-8

ER -